US pharmaceutical giant Pfizer and German biotech company BioNTech today announced test results for the COVID-19 vaccine they are developing. And it’s surprisingly more than 90% effective.
Before that, scientists had only hoped for a COVID-19 vaccine to be 75% effective, while White House senior advisor Dr. Anthony Fauci previously said that a vaccine only needed Efficiency of about 50-60% will be approved.
In the wake of the COVID-19 pandemic that has claimed the lives of more than 1.25 million people worldwide, Dr. Albert Bourla, President and CEO of Pfizer, said: “Today is a great day for science and humanity. I think we can see the light at the end of the tunnel. “
The US stock market immediately rose after the news. Dow Jones industrial index futures rose 1,458 points.
The new COVID-19 vaccine test results by Pfizer and BioNTech are based on the first analysis conducted by an independent Data Monitoring Committee from a third-phase clinical trial. An independent team of experts oversees US clinical trials to ensure the safety of the volunteers participating.
Analysis and evaluation of 94 COVID-19 infections were confirmed among 43,538 study participants. Pfizer and BioNTech said the difference between those vaccinated and those who only received a placebo showed a vaccine efficacy rate of more than 90 percent after 7 days from the second injection.
However, the final efficacy percentage for the vaccine is likely to change, as additional safety and efficacy data are still being collected.
Bourla said in a statement: “Our first set of results from our Phase 3 COVID-19 vaccine trial provides preliminary evidence of COVID-19 prevention.
“We are reaching a milestone in our vaccine development program, at a time when the world needs it most, with infection rates setting new records, hospitals nearing capacity. and economies are struggling to reopen,“Bourla continued.
“With today’s news, we are taking one step closer in providing people around the world with a much-needed breakthrough to end this global health crisis. Over the next few weeks, we will be sharing more data on vaccine efficacy and safety from thousands of participants.
Pfizer and BioNTech report that about 42% of their global test participants have racial and ethnic diversity. There is currently no data from the trial to show that vaccines carry a dangerous complication.
The two companies said they planned to submit an emergency vaccine license to the US Food and Drug Administration (CDC). Based on current forecasts, Pfizer and BioNTech are expected to produce up to 50 million doses of vaccine by 2020 and up to 1.3 billion doses by 2021.
US officials and scientists hope the United States will have a vaccine to prevent COVID-19 in the first half of 2021, which is about 12 to 18 months since Chinese scientists first appeared. first identified and mapped the genetic sequence of the SARS-CoV-2 virus.
If this goal is met, it will be a record time for a vaccine to be successfully developed. The fastest development of the vaccine ever is in mumps, when it took scientists just over four years to research, test and license it in 1967.